Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases

Cytokine and Growth Factor Reviews

Volumn 24, Issue 6, 2013, Pages 515-522

  Pan, Hai Feng ^a   Leng, Rui Xue ^a   Li, Xiang Pei ^b   Zheng, Song Guo ^c,d   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c TONGJI UNIVERSITY   (China)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Autoimmune; IL 9; Th9; Therapeutic

Indexed keywords

CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR6; IMMUNOSUPPRESSIVE AGENT; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 9; INTERLEUKIN 9 ANTIBODY; INTERLEUKIN 9 RECEPTOR; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR PU 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL LINEAGE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DERMATITIS; DISEASE COURSE; EFFECTOR CELL; EPIDERMIS HYPERPLASIA; HELPER CELL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TH17 CELL; TH9 CELL;

ANIMALS; ANTIGENS, CD4; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; HUMANS; INTERLEUKIN-9; MICE; RECEPTORS, INTERLEUKIN-9; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84888305231     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.09.001     Document Type: Short Survey

References (106)

1. Craft J.E. Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol 2012, 8:337-347.
2. Pan H.F., Ye D.Q., Li X.P. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008, 4:352-353.
3. Henriques A., Ines L., Pais M.L., da Silva J.A., Paiva A.A. Th17 cells in systemic lupus erythematosus share functional features with Th17 cells from normal bone marrow and peripheral tissues. Clin Rheumatol 2012, 31:483-491.
4. Xing Q., Wang B., Su H., Cui J., Li J. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int 2012, 32:949-958.
5. Wong C.K., Lit L.C., Tam L.S., Li E.K., Wong P.T., Lam C.W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008, 127:385-393.
6. Yang J., Chu Y., Yang X., Gao D., Zhu L., Wan L., et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1472-1483.
7. Zhang N., Pan H.F., Ye D.Q. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem 2011, 353:41-46.
8. Yang X.Y., Wang H.Y., Zhao X.Y., Wang L.J., Lv Q.H., Wang Q.Q. Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus. J Clin Immunol 2013, 33:767-774.
9. Zhao L., Jiang Z., Jiang Y., Ma N., Wang K., Zhang Y., et al. IL-22+ CD4+ T-cells in patients with active systemic lupus erythematosus. Exp Biol Med (Maywood) 2013, 238:193-199.
10. Pan H.F., Li X.P., Zheng S.G., Ye D.Q. Emerging role of interleukin-22 in autoimmune diseases. Cytokine Growth Factor Rev 2013, 24:51-57.
11. Arroyo-Villa I., Bautista-Caro M.B., Balsa A., Aguado-Acin P., Nuno L., Bonilla-Hernan M.G., et al. Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivity. PLoS ONE 2012, 7:e42189.
12. Pernis A.B. Th17 cells in rheumatoid arthritis and systemic lupus erythematosus. J Intern Med 2009, 265:644-652.
13. van Hamburg J.P., Asmawidjaja P.S., Davelaar N., Mus A.M., Colin E.M., Hazes J.M., et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011, 63:73-83.
14. von Delwig A., Locke J., Robinson J.H., Ng W.F. Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010, 62:143-149.
15. Zhang L., Li J.M., Liu X.G., Ma D.X., Hu N.W., Li Y.G., et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:606-614.
16. Zhang L., Li Y.G., Li Y.H., Qi L., Liu X.G., Yuan C.Z., et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS ONE 2012, 7:e31000.
17. Conti L., De Palma R., Rolla S., Boselli D., Rodolico G., Kaur S., et al. Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-gammaR2. J Immunol 2012, 188:1011-1018.
18. Darlington P.J., Touil T., Doucet J.S., Gaucher D., Zeidan J., Gauchat D., et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013, 73:341-354.
19. Drulovic J., Savic E., Pekmezovic T., Mesaros S., Stojsavljevic N., Dujmovic-Basuroski I., et al. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment. J Neuroimmunol 2009, 215:90-95.
20. Esendagli G., Kurne A.T., Sayat G., Kilic A.K., Guc D., Karabudak R. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy. J Neuroimmunol 2013, 255:81-84.
21. Li Y., Wang H., Long Y., Lu Z., Hu X. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2011, 234:155-160.
22. Xueyi L., Lina C., Zhenbiao W., Qing H., Qiang L., Zhu P. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-alpha therapy. J Clin Immunol 2013, 33:151-161.
23. Shen H., Goodall J.C., Hill Gaston J.S. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009, 60:1647-1656.
24. Ciccia F., Accardo-Palumbo A., Giardina A., Di Maggio P., Principato A., Bombardieri M., et al. Expansion of intestinal CD4+ CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. Arthritis Rheum 2010, 62:3625-3634.
25. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010, 130:1373-1383.
26. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009, 129:1339-1350.
27. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008, 118:597-607.
28. Zhang L., Yang X.Q., Cheng J., Hui R.S., Gao T.W. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol 2010, 135:108-117.
29. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Abello M.V., Novitskaya I., Pierson K.C., et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009, 129:79-88.
30. Eyerich S., Eyerich K., Pennino D., Carbone T., Nasorri F., Pallotta S., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009, 119:3573-3585.
31. Zheng S.G., Gray J.D., Ohtsuka K., Yamagiwa S., Horwitz D.A. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol 2002, 169:4183-4189.
32. Zheng S.G., Wang J., Wang P., Gray J.D., Horwitz D.A. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007, 178:2018-2027.
33. Lan Q., Zhou X., Fan H., Chen M., Wang J., Ryffel B., et al. Polyclonal CD4+Foxp3+ Treg cells induce TGFbeta-dependent tolerogenic dendritic cells that suppress the murine lupus-like syndrome. J Mol Cell Biol 2012, 4:409-419.
34. Kong N., Lan Q., Chen M., Wang J., Shi W., Horwitz D.A., et al. Antigen-specific transforming growth factor beta-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance. Arthritis Rheum 2012, 64:2548-2558.
35. Ouyang H., Shi Y., Liu Z., Feng S., Li L., Su N., et al. Increased interleukin9 and CD4+ IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep 2013, 7:1031-1037.
36. Yanaba K., Yoshizaki A., Asano Y., Kadono T., Sato S. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis. J Rheumatol 2011, 38:2193-2197.
37. Murugaiyan G., Beynon V., Pires Da Cunha A., Joller N., Weiner H.L. IFN-gamma limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol 2012, 189:5277-5283.
38. Goswami R., Kaplan M.H. A brief history of IL-9. J Immunol 2011, 186:3283-3288.
39. Noelle R.J., Nowak E.C. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010, 10:683-687.
40. Jabeen R., Kaplan M.H. The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol 2012, 24:303-307.
41. Kaplan M.H. Th9 cells: differentiation and disease. Immunol Rev 2013, 252:104-115.
42. Stassen M., Schmitt E., Bopp T. From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci 2012, 1247:56-68.
43. Cogan D.G. The rise and fall of eponyms. Arch Ophthalmol 1978, 96:2202-2203.
44. Druez C., Coulie P., Uyttenhove C., Van Snick J. Functional and biochemical characterization of mouse P40/IL-9 receptors. J Immunol 1990, 145:2494-2499.
45. Hultner L., Kolsch S., Stassen M., Kaspers U., Kremer J.P., Mailhammer R., et al. In activated mast cells, IL-1 up-regulates the production of several Th2-related cytokines including IL-9. J Immunol 2000, 164:5556-5563.
46. Mohamadzadeh M., Ariizumi K., Sugamura K., Bergstresser P.R., Takashima A. Expression of the common cytokine receptor gamma chain by murine dendritic cells including epidermal Langerhans cells. Eur J Immunol 1996, 26:156-160.
47. Lee Y.B., Nagai A., Kim S.U. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 2002, 69:94-103.
48. Fontaine R.H., Cases O., Lelievre V., Mesples B., Renauld J.C., Loron G., et al. IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis. Cell Death Differ 2008, 15:1542-1552.
49. Meissner U., Blum H., Schnare M., Rollinghoff M., Gessner A. A soluble form of the murine common gamma chain is present at high concentrations in vivo and suppresses cytokine signaling. Blood 2001, 97:183-191.
50. Yoshimoto T., Min B., Sugimoto T., Hayashi N., Ishikawa Y., Sasaki Y., et al. Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J Exp Med 2003, 197:997-1005.
51. Elyaman W., Bradshaw E.M., Uyttenhove C., Dardalhon V., Awasthi A., Imitola J., et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA 2009, 106:12885-12890.
52. Veldhoen M., Uyttenhove C., van Snick J., Helmby H., Westendorf A., Buer J., et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008, 9:1341-1346.
53. Demoulin J.B., Uyttenhove C., Van Roost E., DeLestre B., Donckers D., Van Snick J., et al. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol Cell Biol 1996, 16:4710-4716.
54. Hornakova T., Staerk J., Royer Y., Flex E., Tartaglia M., Constantinescu S.N., et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem 2009, 284:6773-6781.
55. Adamson A.S., Collins K., Laurence A., O'Shea J.J. The current STATus of lymphocyte signaling: new roles for old players. Curr Opin Immunol 2009, 21:161-166.
56. Hultner L., Druez C., Moeller J., Uyttenhove C., Schmitt E., Rude E., et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 1990, 20:1413-1416.
57. Gessner A., Blum H., Rollinghoff M. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology 1993, 189:419-435.
58. Nowak E.C., Weaver C.T., Turner H., Begum-Haque S., Becher B., Schreiner B., et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009, 206:1653-1660.
59. Beriou G., Bradshaw E.M., Lozano E., Costantino C.M., Hastings W.D., Orban T., et al. TGF-beta induces IL-9 production from human Th17 cells. J Immunol 2010, 185:46-54.
60. Stephens G.L., Swerdlow B., Benjamin E., Coyle A.J., Humbles A., Kolbeck R., et al. IL-9 is a Th17-derived cytokine that limits pathogenic activity in organ-specific autoimmune disease. Eur J Immunol 2011, 41:952-962.
61. Lu L.F., Lind E.F., Gondek D.C., Bennett K.A., Gleeson M.W., Pino-Lagos K., et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006, 442:997-1002.
62. Putheti P., Awasthi A., Popoola J., Gao W., Strom T.B. Human CD4 memory T cells can become CD4+ IL-9+ T cells. PLoS ONE 2010, 5:e8706.
63. Lauwerys B.R., Garot N., Renauld J.C., Houssiau F.A. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol 2000, 165:1847-1853.
64. Jones T.G., Hallgren J., Humbles A., Burwell T., Finkelman F.D., Alcaide P., et al. Antigen-induced increases in pulmonary mast cell progenitor numbers depend on IL-9 and CD1d-restricted NKT cells. J Immunol 2009, 183:5251-5260.
65. Wilhelm C., Hirota K., Stieglitz B., Van Snick J., Tolaini M., Lahl K., et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011, 12:1071-1077.
66. Dardalhon V., Awasthi A., Kwon H., Galileos G., Gao W., Sobel R.A., et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008, 9:1347-1355.
67. Schmitt E., Germann T., Goedert S., Hoehn P., Huels C., Koelsch S., et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol 1994, 153:3989-3996.
68. Chang H.C., Sehra S., Goswami R., Yao W., Yu Q., Stritesky G.L., et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol 2010, 11:527-534.
69. Staudt V., Bothur E., Klein M., Lingnau K., Reuter S., Grebe N., et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 2010, 33:192-202.
70. Tan C., Aziz M.K., Lovaas J.D., Vistica B.P., Shi G., Wawrousek E.F., et al. Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J Immunol 2010, 185:6795-6801.
71. Tan C., Gery I. The unique features of Th9 cells and their products. Crit Rev Immunol 2012, 32:1-10.
72. Goswami R., Jabeen R., Yagi R., Pham D., Zhu J., Goenka S., et al. STAT6-dependent regulation of Th9 development. J Immunol 2012, 188:968-975.
73. Chang H.C., Zhang S., Thieu V.T., Slee R.B., Bruns H.A., Laribee R.N., et al. PU.1 expression delineates heterogeneity in primary Th2 cells. Immunity 2005, 22:693-703.
74. Chang H.C., Han L., Jabeen R., Carotta S., Nutt S.L., Kaplan M.H. PU.1 regulates TCR expression by modulating GATA-3 activity. J Immunol 2009, 183:4887-4894.
75. Wei J., Duramad O., Perng O.A., Reiner S.L., Liu Y.J., Qin F.X. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2007, 104:18169-18174.
76. O'Malley J.T., Sehra S., Thieu V.T., Yu Q., Chang H.C., Stritesky G.L., et al. Signal transducer and activator of transcription 4 limits the development of adaptive regulatory T cells. Immunology 2009, 127:587-595.
77. Angkasekwinai P., Chang S.H., Thapa M., Watarai H., Dong C. Regulation of IL-9 expression by IL-25 signaling. Nat Immunol 2010, 11:250-256.
78. Perumal N.B., Kaplan M.H. Regulating Il9 transcription in T helper cells. Trends Immunol 2011, 32:146-150.
79. Jager A., Dardalhon V., Sobel R.A., Bettelli E., Kuchroo V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009, 183:7169-7177.
80. Kara E.E., Comerford I., Bastow C.R., Fenix K.A., Litchfield W., Handel T.M., et al. Distinct chemokine receptor axes regulate th9 cell trafficking to allergic and autoimmune inflammatory sites. J Immunol 2013, 191:1110-1117.
81. Locksley R.M. Nine lives: plasticity among T helper cell subsets. J Exp Med 2009, 206:1643-1646.
82. Li H., Nourbakhsh B., Ciric B., Zhang G.X., Rostami A. Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol 2010, 185:4095-4100.
83. Townsend J.M., Fallon G.P., Matthews J.D., Smith P., Jolin E.H., McKenzie N.A. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000, 13:573-583.
84. Matsuzawa S., Sakashita K., Kinoshita T., Ito S., Yamashita T., Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 2003, 170:3461-3467.
85. Singh T.P., Schon M.P., Wallbrecht K., Gruber-Wackernagel A., Wang X.J., Wolf P. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS ONE 2013, 8:e51752.
86. Cheng F., Guo Z., Xu H., Yan D., Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009, 68:604-606.
87. Huang X., Hua J., Shen N., Chen S. Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients. Mod Rheumatol 2007, 17:220-223.
88. Tete S., Saggini A., Maccauro G., Rosati M., Conti F., Cianchetti E., et al. Interleukin-9 and mast cells. J Biol Regul Homeost Agents 2012, 26:319-326.
89. Knoops L., Louahed J., Renauld J.C. IL-9-induced expansion of B-1b cells restores numbers but not function of B-1 lymphocytes in xid mice. J Immunol 2004, 172:6101-6106.
90. Vink A., Warnier G., Brombacher F., Renauld J.C. Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population. J Exp Med 1999, 189:1413-1423.
91. Dugas B., Renauld J.C., Pene J., Bonnefoy J.Y., Peti-Frere C., Braquet P., et al. Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol 1993, 23:1687-1692.
92. Petit-Frere C., Dugas B., Braquet P., Mencia-Huerta J.M. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology 1993, 79:146-151.
93. Fawaz L.M., Sharif-Askari E., Hajoui O., Soussi-Gounni A., Hamid Q., Mazer B.D. Expression of IL-9 receptor alpha chain on human germinal center B cells modulates IgE secretion. J Allergy Clin Immunol 2007, 120:1208-1215.
94. Gounni A.S., Hamid Q., Rahman S.M., Hoeck J., Yang J., Shan L. IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. J Immunol 2004, 173:2771-2779.
95. Baraldo S., Faffe D.S., Moore P.E., Whitehead T., McKenna M., Silverman E.S., et al. Interleukin-9 influences chemokine release in airway smooth muscle: role of ERK. Am J Physiol Lung Cell Mol Physiol 2003, 284:L1093-L1102.
96. Cope A.P., Feldmann M. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr Opin Immunol 2004, 16:780-786.
97. Chatenoud L. Immune therapies of autoimmune diseases: are we approaching a real cure. Curr Opin Immunol 2006, 18:710-717.
98. Kunz M., Ibrahim S.M. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm 2009, 2009:979258.
99. Yang Y., Du L., Sun M., Kijlstra A., Yang P. IFN-beta inhibits the increased expression of IL-9 during experimental autoimmune uveoretinitis. PLoS ONE 2012, 7:e48566.
100. Lisi S., Sisto M., Lofrumento D.D., D'Amore M. Sjogren's syndrome autoantibodies provoke changes in gene expression profiles of inflammatory cytokines triggering a pathway involving TACE/NF-kappaB. Lab Invest 2012, 92:615-624.
101. Li H., Nourbakhsh B., Cullimore M., Zhang G.X., Rostami A. IL-9 is important for T-cell activation and differentiation in autoimmune inflammation of the central nervous system. Eur J Immunol 2011, 41:2197-2206.
102. Gironi M., Saresella M., Rovaris M., Vaghi M., Nemni R., Clerici M., et al. A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis. Immun Ageing 2013, 10:1.
103. Zhu W., Liu N., Zhao Y., Jia H., Cui B., Ning G. Association analysis of polymorphisms in IL-3, IL-4, IL-5, IL-9, and IL-13 with Graves' disease. J Endocrinol Invest 2010, 33:751-755.
104. McDonnell G.V., Kirk C.W., Hawkins S.A., Graham C.A. An evaluation of interleukin genes fails to identify clear susceptibility loci for multiple sclerosis. J Neurol Sci 2000, 176:4-12.
105. Ryan A.W., Thornton J.M., Brophy K., Daly J.S., McLoughlin R.M., O'Morain C., et al. Chromosome 5q candidate genes in coeliac disease: genetic variation at IL4, IL5, IL9, IL13, IL17B and NR3C1. Tissue Antigens 2005, 65:150-155.
106. Burkhardt J., Petit-Teixeira E., Teixeira V.H., Kirsten H., Garnier S., Ruehle S., et al. Association of the X-chromosomal genes TIMP1 and IL9R with rheumatoid arthritis. J Rheumatol 2009, 36:2149-2157.